이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

고급 고형 종양용 PRO1184 (RAINFOL-01)

2026년 11월 2일 업데이트: Genmab

국소 진행성 및/또는 전이성 고형 종양 환자에서 PRO1184의 1/2상 연구

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.

Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This is a Phase 1/2 study of Rina-S; also known as GEN1184, formerly known as PRO1184, a folate receptor alpha (FRα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Rina-S in participants with selected locally advanced and/or metastatic solid tumors, including epithelial ovarian cancer, endometrial cancer, breast cancer, non-small cell lung cancer, and mesothelioma.

The study consists of multiple parts:

Part A: monotherapy cohorts

Part B: tumor-specific monotherapy dose-expansion cohorts

Part C: platinum-resistant ovarian cancer (PROC) monotherapy cohort

Part D: combination therapy cohorts

Part E: a monotherapy PROC cohort

Parts F and G: a monotherapy endometrial cancer (EC) cohort

Part H: a monotherapy PROC cohort

Part I: platinum-sensitive ovarian cancer (PSOC) cohort

Part J: a monotherapy PROC cohort

Part K: a monotherapy high-grade ovarian cancer cohort

Part L: a drug-drug interaction substudy

Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.

연구 유형

중재적

등록 (추정된)

952

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

  • 대한민국
      • Seoul, 대한민국
        • 모병
        • Korea Institute of Radiological and Medical Sciences
  • 미국
    • Arizona
      • Phoenix, Arizona, 미국, 85016
        • 모병
        • USOR HonorHealth
      • Tucson, Arizona, 미국, 85711
        • 모병
        • USOR Arizona Oncology Associates
    • California
      • Los Angeles, California, 미국, 90095
        • 모병
        • University of California Los Angeles Medical Center
      • San Diego, California, 미국, 92093
        • 모병
        • University of California, San Diego; Moores Cancer Center
      • Santa Barbara, California, 미국, 93105
        • 모병
        • USOR Sansum Clinic
      • Santa Rosa, California, 미국, 95403
        • 모병
        • Providence Medical Foundation
    • Florida
      • Fort Myers, Florida, 미국, 33908
        • 모병
        • USOR Florida Cancer Specialists South
      • St. Petersburg, Florida, 미국, 33709
        • 모병
        • USOR Florida Cancer Specialists North
      • West Palm Beach, Florida, 미국, 33401
        • 모병
        • USOR Florida Cancer Specialists East
    • Georgia
      • Augusta, Georgia, 미국, 30912
        • 모병
        • Augusta University Georgia Cancer Center
    • Kansas
      • Westwood, Kansas, 미국, 66205
        • 모병
        • University of Kansas Medical Center (KUMC)
    • Maryland
      • Rockville, Maryland, 미국, 20850
        • 모병
        • USOR Maryland Oncology Hematology
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital
      • Boston, Massachusetts, 미국, 02215
        • 모병
        • Dana Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, 미국, 48085
        • 모병
        • Karmanos Cancer Institute
      • Grand Rapids, Michigan, 미국, 49503
        • 모병
        • START Midwest
    • Minnesota
      • Maplewood, Minnesota, 미국, 55109
        • 모병
        • USOR Minnesota Oncology Hematology
    • New Jersey
      • Camden, New Jersey, 미국, 08103
        • 모병
        • MD Anderson Cancer Center at Cooper- Two Cooper Plaza
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • 모병
        • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • 모병
        • University of Oklahoma - Health Sciences Center
    • Oregon
      • Eugene, Oregon, 미국, 97401
        • 모병
        • USOR Oncology Associates of Oregon, P.C.
      • Portland, Oregon, 미국, 97227
        • 모병
        • Compass Oncology - Rose Quarter
    • Pennsylvania
      • Doylestown, Pennsylvania, 미국, 18901
        • 모병
        • USOR Alliance Cancer Specialist
      • Pittsburgh, Pennsylvania, 미국, 15224
        • 모병
        • Allegheny Health Network
    • Rhode Island
      • Providence, Rhode Island, 미국, 02905
        • 모병
        • Women and Infants Hospital of Rhode Island
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Tennessee Oncology
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Sarah Cannon Research Institute at Tennessee Oncology
    • Texas
      • Abilene, Texas, 미국, 79606
        • 모병
        • USOR Texas Oncology
      • Austin, Texas, 미국, 78758
        • 모병
        • Texas Oncology - Central / South Texas
      • Dallas, Texas, 미국, 75521
        • 모병
        • Mary Crowley Cancer Research
      • Fort Worth, Texas, 미국, 76104
        • 모병
        • USOR Texas Oncology
      • Tyler, Texas, 미국, 75702
        • 모병
        • Texas Oncology - Northeast TX
      • Woodland, Texas, 미국, 77380
        • 모병
        • USOR Texas Oncology Gulf Coast
    • Utah
      • West Valley City, Utah, 미국, 84119
        • 모병
        • START Mountain Region
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • 모병
        • USOR Virginia Cancer Specialists
      • Norfolk, Virginia, 미국, 23502
        • 모병
        • USOR Virginia Oncology Associates
    • Washington
      • Everett, Washington, 미국, 98104
        • 모병
        • Swedish Cancer Institute
  • 일본
    • Fukushima
      • Fukushima, Fukushima, 일본
        • 모병
        • Fukushima Medical University Hospital
    • Gunma
      • Ōta, Gunma, 일본
        • 모병
        • Gunma Prefectural Cancer Center
    • Hokkaido
      • Sapporo, Hokkaido, 일본
        • 모병
        • Sapporo Medical University Hospital
    • Hyōgo
      • Akashi, Hyōgo, 일본
        • 모병
        • Hyogo Cancer Center
    • Saitama
      • Hidaka, Saitama, 일본
        • 모병
        • Saitama Medical University-International Medical Center
    • Shizuoka
      • Nagaizumi-chō, Shizuoka, 일본
        • 모병
        • Shizuoka Cancer Center
    • Tokyo
      • Koto, Tokyo, 일본
        • 모병
        • Cancer Institute Hospital of JFCR
      • Shinjuku-ku, Tokyo, 일본
        • 모병
        • Keio University Hospital
    • Yamagata
      • Yamagata, Yamagata, 일본
        • 모병
        • Yamagata University Hospital
  • 중국
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국
        • 모병
        • Cancer hospital, Chinese Academy of Medical Sciences
    • China
      • Fujian, China, 중국
        • 모병
        • Fujian Cancer Hospital
      • Guangdong, China, 중국
        • 모병
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      • Henan, China, 중국
        • 모병
        • Second Affiliated Hospital of Zhengzhou University
      • Hubei, China, 중국
        • 모병
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Shanxi, China, 중국
        • 모병
        • Second Hospital of Shanxi Medical University
      • Shanxi, China, 중국
        • 모병
        • Shanxi Cancer Hospital
      • Shengyang, China, 중국
        • 모병
        • Liaoning Cancer Hospital & Institute
      • Tianjin, China, 중국
        • 모병
        • Tianjin Cancer Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, 중국
        • 모병
        • Chongqing University Cancer Hospital
    • Hunan
      • Changsha, Hunan, 중국
        • 모병
        • Hunan Cancer Hospital - Phase 1
      • Changsha, Hunan, 중국
        • 모병
        • Hunan Cancer Hospital - Thoracic Medicine Dept II
    • Jiangxi
      • Nanchang, Jiangxi, 중국
        • 모병
        • Jiangxi Maternal and Child Health Hospital
    • Jilin
      • Changchun, Jilin, 중국
        • 모병
        • Jilin Cancer Hospital
    • Shanghai Municipality
      • Chengdu, Shanghai Municipality, 중국
        • 모병
        • Obstetrics & Gynecology Hospital of Fudan University
      • Shanghai, Shanghai Municipality, 중국
        • 모병
        • Fudan University Shanghai Cancer Center - Gynecologic Oncology
      • Shanghai, Shanghai Municipality, 중국
        • 모병
        • Fudan University Shanghai Cancer Center- Phase 1
      • Shanghai, Shanghai Municipality, 중국
        • 모병
        • Shanghai East Hospital
    • Sichuan
      • Shanghai, Sichuan, 중국
        • 모병
        • Sichuan Cancer Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, 중국
        • 모병
        • Zhejiang Cancer Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Part A and B:

  • Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negative) (Part A), mesothelioma or cervical cancer (Part B).
  • Previously received therapies known to confer clinical benefit.
  • Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.

Part C, E, and H:

Participants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below.

  • High grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)
  • Participants must have received up to 3 prior lines of therapy. Participants may have had up to to 4 prior lines of therapy are allowed if MIRV is locally approved and was used as the last line of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.
  • Participants must have platinum-resistant ovarian cancer.
  • Participants must have received prior bevacizumab or approved biosimilar.
  • Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration [FDA]-approved test in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory; or locally approved equivalent) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.
  • Measurable disease per the RECIST v1.1 at baseline.

Part D:

Cohort D1:

  • Participants must have platinum-sensitive ovarian cancer.
  • Participants must have received 1 to 3 prior lines of therapy.

Cohort D2:

  • Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.

  • Participants with primary platinum-refractory ovarian cancer must have received ≤2 prior lines of therapy. Primary platinum-refractory ovarian cancer is defined as a lack of response or by progression within 91 days after completing front-line platinum containing therapy.

  • Participants must have received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer (PROC), and up to 4 prior lines of therapy for platinum-sensitive ovarian cancer (PSOC). Prior treatments may have included bevacizumab, PARP inhibitor, and MIRV.

    • Participants with PSOC must have disease progression on or after maintenance treatment, or at least 6 months (>183 days) or more from the last dose of platinum-based therapy.

Cohort D3:

• Endometrial cancer (any subtype excluding sarcoma).

Cohort D4:

• Primary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).

Cohort D5

• Primary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).

Part F and G:

  • Participants must have histologically or cytologically confirmed EC.
  • Recurrent progressive EC (any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) following prior therapy.
  • Participants must have received 1 to 3 prior lines of therapy, and must have progressed radiographically on or after their most recent line of therapy:
  • Participants must have received prior platinum-based chemotherapy and a programmed death-ligand 1 (PD-[L])1 inhibitor.
  • Participants who progress >12 months after completion of prior adjuvant or neoadjuvant platinum-based chemotherapy must receive 1 additional cytotoxic systemic treatment prior to enrollment in this study.
  • Hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy.
  • Measurable disease per the RECIST Version 1.1 at baseline.

Part I:

  • Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer (excluding clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies or low grade/borderline ovarian tumors).
  • Participants must have platinum sensitive ovarian cancer.
  • Measurable disease per the RECIST Version 1.1 at baseline.

Part J:

  • Participants must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element.
  • Measurable disease per the RECIST Version 1.1 at baseline.

Part K:

  • Participants must have histologically or cytologically confirmed metastatic or unresectable ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element).
  • Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.
  • Measurable disease per the RECIST Version 1.1 at baseline.

Part L:

  • Participants must have a histologically or cytologically confirmed metastatic or unresectable solid malignancy. Participants must have previously received all therapies known to confer clinical benefit (unless ineligible to receive or refused to receive or therapy is unavailable in the region). If a standard-of-care therapy is available that has not been administered, the reason that the therapy is not appropriate must be documented.
  • Participants must either have ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element), or
  • NSCLC.
  • Age 18 to 65 years (inclusive).
  • An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
  • Measurable disease per the RECIST version 1.1 at baseline.

Exclusion Criteria:

  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids within the past 2 years, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.

Note: Other protocol-defined inclusion/exclusion may apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part A, B, C, E, F, G, H, I, J and K

Rina-S monotherapy in Part A and at the recommended dose in Parts B, C, E, F, G, H, I, J and K.
의약품: Rina-S

Intravenous infusion of Rina-S

다른 이름들:
  • PRO1184
  • GEN1184
  • 리나타바트 세스테칸
실험적: Part D1

Rina-S in combination with carboplatin
의약품: Rina-S

Intravenous infusion of Rina-S

다른 이름들:
  • PRO1184
  • GEN1184
  • 리나타바트 세스테칸
의약품: Carboplatin

Carboplatin intravenous infusion
실험적: Part D2 and I

Rina-S in combination with bevacizumab
의약품: Rina-S

Intravenous infusion of Rina-S

다른 이름들:
  • PRO1184
  • GEN1184
  • 리나타바트 세스테칸
의약품: Bevacizumab

Bevacizumab intravenous infusion
실험적: Part D3, D4 and D5

Rina-S in combination with pembrolizumab
의약품: Rina-S

Intravenous infusion of Rina-S

다른 이름들:
  • PRO1184
  • GEN1184
  • 리나타바트 세스테칸
의약품: Pembrolizumab

Pembrolizumab intravenous infusion
실험적: Part L

Rina-S in combination with CYP3A4 inhibitors erythromycin or itraconazole.
의약품: Rina-S

Intravenous infusion of Rina-S

다른 이름들:
  • PRO1184
  • GEN1184
  • 리나타바트 세스테칸
의약품: Erythromycin

Erythromycin oral administration

의약품: Itraconazole

Itraconazole oral administration

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
부품 A, B 및 D- 치료 응급 부작용 (TEAES)의 발생률 [안전성 및 내약성]
기간: 치료 종료를 통해 최대 약 1 년.
치료 종료를 통해 최대 약 1 년.
Part K (미국 참가자 전용) - 홀터의 임상 적으로 유의미한 변화가있는 참가자 수
기간: 사이클 1 ~ 3 (각주기는 21 일)
사이클 1 ~ 3 (각주기는 21 일)
Parts A, and D - Number of Participants with Dose Limiting Toxicity (DLT)
기간: At the end of Cycle 1 (each cycle is 21 days)
At the end of Cycle 1 (each cycle is 21 days)
Parts C, E, F, G, H, I, and J- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR, Parts C and F) or Investigator (Part E, G, I, and J) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
기간: Through end of treatment, up to approximately 1 year.

Participants who achieve partial response (PR) or complete response (CR) per RECIST v1.1 criteria.
Through end of treatment, up to approximately 1 year.
Part L - Peak Plasma Concentration (Cmax) of Rina-S
기간: Cycles 1 and 2 (each cycle is 21 days)

Measurement of maximum plasma concentration after the administration of Rina-S.[
Cycles 1 and 2 (each cycle is 21 days)
Part L - Area Under the Plasma Concentration Versus Time Curve (AUC) of Rina-S
기간: Cycles 1 and 2 (each cycle is 21 days)

Measurement of AUC after the administration of Rina-S.
Cycles 1 and 2 (each cycle is 21 days)

2차 결과 측정

결과 측정
측정값 설명
기간
Parts A, B, D, and E -Time to Reach Cmax (Tmax) for Rina-S
기간: Through end of treatment, up to approximately 1 year
Through end of treatment, up to approximately 1 year
Parts A, B, D, and E - Trough Concentrations (Ctrough) for Rina-S
기간: Through end of treatment, up to approximately 1 year
Through end of treatment, up to approximately 1 year
Parts A, B, D, and E- Apparent Terminal Half-life (t1/2) for Rina-S
기간: Through end of treatment, up to approximately 1 year
Through end of treatment, up to approximately 1 year
Parts C, D, E, H and J - CA-125 Response Determined Using the Gynecologic Cancer Intergroup (GCIG) Criteria
기간: Through end of treatment, up to approximately 1 year
Through end of treatment, up to approximately 1 year
Part E - Number of Participants With Antidrug Antibodies (ADA)
기간: Through end of treatment, up to approximately 1 year
Through end of treatment, up to approximately 1 year
Parts A, B, and D - Best Overall Response (BOR)
기간: Up to approximately 1 year.

Participants who achieve CR or PR. Best response as assessed by the investigator per RECIST v1.1 criteria for all tumor types other than pleural mesothelioma which will use modified RECIST (mRECIST) v1.1.
Up to approximately 1 year.
Parts A, B, D, and E - ORR
기간: Up to approximately 1 year.

Participants who achieve PR or CR per RECIST v1.1 criteria.
Up to approximately 1 year.
Parts A, B, and D - Disease Control Rate (DCR)
기간: Up to approximately 1 year.

Participants who achieve stable disease, PR or CR per RECIST v1.1 criteria.
Up to approximately 1 year.
Parts A, B, C, D, E, F, G, H, I, and J - Progression-Free Survival (PFS)
기간: Through end of treatment, up to approximately 1 year.

Time from start of treatment to first documented disease progression or death
Through end of treatment, up to approximately 1 year.
Parts C, E, F, G, H, I and J - Overall survival (OS)
기간: Up to approximately 2 years.

Time from the start of study treatment to the date of death from any cause
Up to approximately 2 years.
Parts A, B, C, D, E, F, G, H, I and J - Duration of Objective Response (DOR)
기간: From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months.

Time from the first documentation of an objective tumor response (CR or PR) to the first documented tumor progression or death
From date of enrollment until the date of first documented disease progression or date of study withdrawal, whichever came first, assessed up to 12 months.
Parts A, B, D, and E - Cmax for Rina-S
기간: Through end of treatment, up to approximately 1 year.

Measurement of maximum plasma concentration after the administration of Rina-S.
Through end of treatment, up to approximately 1 year.
Parts A, B, D, and E - AUC for Rina-S
기간: Through end of treatment, up to approximately 1 year.

Measurement of AUC after the administration of Rina-S.
Through end of treatment, up to approximately 1 year.
Parts C, E, F, G, H, I, J, K and L - Number of Participants with Type, Incidence, Severity, Seriousness as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and Relatedness of Adverse Events (AEs)
기간: Through end of treatment, up to approximately 1 year
Through end of treatment, up to approximately 1 year
Part L - Number of Participants with DLT
기간: At the end of Cycle 1 (each cycle is 21 days)
At the end of Cycle 1 (each cycle is 21 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Genmab

수사관

  • 연구 책임자: Study Official, Genmab

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 12월 7일

기본 완료 (추정된)

2028년 12월 1일

연구 완료 (추정된)

2029년 3월 1일

연구 등록 날짜

최초 제출

2022년 10월 4일

QC 기준을 충족하는 최초 제출

2022년 10월 11일

처음 게시됨 (실제)

2022년 10월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • GCT1184-01
  • PRO1184-001 (기타 식별자: Other Sponsor Identifier)
  • CTR20230813 (레지스트리 식별자: Chinadrugtrials.org.cn)
  • jRCT2051250094 (레지스트리 식별자: Japan Registry for Clinical Trials (jRCT))

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다